Aria Pharmaceuticals

17/12/2021

2021 was a transformational year for Aria. CEO Andrew Radin penned his thoughts on this year's accomplishments and looks ahead at what's to come in the future.

By: Andrew A Radin

26/08/2021

We are pleased to announce positive efficacy and tolerability of two novel compounds for - the latest program to advance in our pipeline of diseases.

TXR-1002 and TXR-1007, demonstrated significant efficacy and excellent tolerability in preclinical studies.

21/07/2021

Today is Glioblastoma (GBM) Awareness Day and we’re passionate about advancing our pre-clinical development program to bring new treatments to patients in need. https://ariapharmaceuticals.com/three-novel-glioblastoma-treatment-candidates-into-in-vivo-testing/

10/06/2021

Non-alcoholic steatohepatitis (NASH) is an advanced form of non-alcoholic fatty liver disease (NAFLD), with an immediate need for treatment options. Get to know and why we are excited about two promising novel treatment candidates from our preclinical program. Check out our latest preclinical results here:https://staticmedia.ariapharmaceuticals.com/wp-content/uploads/2021/02/16091139/NASH-poster-Final_2.pdf

25/05/2021

This we celebrate those working to address the unmet need for better treatment options in . Dr. Strand shares why this is so important to improve care for her patients.

13/05/2021

May is . The complexity of often makes it difficult to diagnose and difficult to treat, leaving patients in need of new therapies. At Aria we’re committed to advancing two novel candidates from our pipeline as potential treatments for lupus.

05/05/2021

Aria Pharmaceuticals CEO, Andrew Radin, talks about the exciting new era for the company. Our transition will focus on advancing our own pipeline of novel drug candidates through sound science.
https://endpts.com/andrew-radin-orchestrates-his-ai-discovery-platforms-pivot-to-rd-with-a-harmonious-name-change-and-eyes-on-the-clinic/

03/05/2021

BIG ANNOUNCEMENT: We are excited to announce that twoXAR Pharmaceuticals is now Aria Pharmaceuticals! Our name reflects the artistry and complexity that defines how we approach medicine from discovery to FDA approval in a way that is scientifically sound. In tandem, we have expanded our pipeline to include novel preclinical compounds targeting fibrotic and immunological diseases and transitioning from discovery collaborations to developing our own pipeline from IND-enabling studies through to clinical research.

Aria Pharmaceuticals will transition from drug discovery partnerships to advancing its own novel therapies in an expanding pipeline across 18 different therapeutic programs